乳腺癌根治术后单纯肝转移患者的治疗转归：一项回顾性分析。
Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis.
机构信息
Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People's Republic of China.
出版信息
J Cancer Res Clin Oncol. 2011 Sep;137(9):1363-70. doi: 10.1007/s00432-011-1008-y. Epub 2011 Jul 26.
PURPOSE
To evaluate the efficiency of combined treatment of transcatheter arterial chemoembolization (TACE) and systemic chemotherapy (SC) for liver-only metastases from breast cancer after mastectomy.
METHODS
We compared the outcomes of 44 patients who underwent combined treatment of TACE and systemic chemotherapy (TSC) with those of 43 patients who underwent systemic chemotherapy (SC).
RESULTS
The median follow-up from the diagnosis of liver metastases was 29 months (range, 0-89 months). Response rates were 59.1% and 34.9% for TSC group and SC group (P < 0.05), respectively. The 1-, 2- and 3-year survival rates for TSC group were 76.2, 66.7 and 47.6%, and those for SC group were 48.1, 29.6 and 7.4% (P = 0.027), respectively. Estrogen receptor (ER)-negative status of primary tumor, disease-free interval from mastectomy to liver metastases (DFI) less than 24 months and patients who received systemic chemotherapy only were independently associated with poor prognosis (P = 0.009; P = 0.023; P = 0.030).
CONCLUSIONS
The combined treatment of TACE and systemic chemotherapy may prolong survival for liver metastases in breast cancer after mastectomy.
目的
评估乳腺癌根治术后单纯肝转移患者经肝动脉化疗栓塞（TACE）联合全身化疗（SC）治疗的疗效。
方法
我们比较了 44 例接受 TACE 联合全身化疗（TSC）治疗和 43 例接受全身化疗（SC）治疗的患者的结局。
结果
从肝转移诊断到中位随访时间为 29 个月（范围 0-89 个月）。TSC 组和 SC 组的有效率分别为 59.1%和 34.9%（P<0.05）。TSC 组的 1、2、3 年生存率分别为 76.2%、66.7%和 47.6%，SC 组分别为 48.1%、29.6%和 7.4%（P=0.027）。原发肿瘤雌激素受体（ER）阴性、从乳腺癌根治术到肝转移的无病间隔（DFI）<24 个月以及仅接受全身化疗的患者与预后不良独立相关（P=0.009；P=0.023；P=0.030）。
结论
TACE 联合全身化疗可能延长乳腺癌根治术后单纯肝转移患者的生存时间。
Zotero 插件